Low dose radioactive iodine-131 (RAI) has been widely reported in the treatment of patients
with differentiated thyroid cancer (DTC) since 1970′ s. However, the clinical outcomes …

Objective: Since the 1970s, low dose radioactive iodine-131 (RAI or I 131) has been widely
reported in the treatment of patients with differentiated thyroid cancer (DTC). However, the …

To evaluate treatment outcomes following radioactive iodine (RAI) treatment with a
cumulative dose of≥≥ 600 mCi in differentiated thyroid carcinoma (DTC) patients, a …

Background: The management of patients with differentiated thyroid cancer (DTC) has been
changing in recent years and aggressiveness of treatment depends on the risk of persistent …

Objectives To compare the ablation results, therapeutic responses and adverse reactions
between a low dose (1.1 GBq) or high dose (3.7 GBq) of 131 I in low-/intermediate-risk …

Abstract 131 Objective: Radioiodine (I) is considered an e ective and low-risk therapeutic
radionuclide for di erentiated thyroid carcinoma (DTC); however, dilemmas exist in the …

Radioactive iodine (RAI) therapy for differentiated thyroid cancer has been successfully
used for more than 70 years. However, there is still plenty of controversy surrounding the …

Objective We conducted a stratified randomized equivalence/noninferiority trial from January
2001 to December 2006 to determine whether lower administered activities are as effective …

155 Objectives To compare the early outcome between patients who received 100 mCi and
150 mCi for postsurgical I-131 radioiodine ablation (RAI) in differentiated thyroid carcinoma …

The use of radioiodine (I-131) in the management of patients suffering differentiated thyroid
cancer (DTC) has changed little in the past 40 years. The use of a standardized approach …